Network for Excellence in Neuroscience Clinical Trials Center at The Ohio State University

俄亥俄州立大学神经科学临床试验中心卓越网络

• 批准号: 9572867
• 负责人: Stephen J. Kolb
• 金额: $ 32.27万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9572867
• 关键词: Adult; Advocacy; Advocate; Affect; Age-Months; Area; Biometry; Child; Childhood; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Data; Development; Development Plans; Diagnosis; Educational Curriculum; Enrollment; Fellowship; Five-Year Plans; Funding; Future; Grant; Human Resources; Individual; Infant; Influentials; Investments; K-Series Research Career Programs; Leadership; Link; Medical center; Mentors; Mentorship; Morals; Motor Neuron Disease; National Institute of Neurological Disorders and Stroke; Natural History; Neurologic; Neurology; Neurosciences; Nursery Schools; Ohio; Patients; Pediatric Hospitals; Performance; Phase; Physicians; Principal Investigator; Protocols documentation; Randomized; Research; Research Infrastructure; Research Institute; Research Personnel; Site; Spinal Muscular Atrophy; Time; TimeLine; Training; Training and Infrastructure; United States National Institutes of Health; Universities; Update; career development; cohort; design; expectation; experience; innovation; interest; nervous system disorder; outreach; programs; recruit; success

The Network of Excellence in Neuroscience Clinical Trial Center at The Ohio State University is one of the original NeuroNEXT centers and maintains a strong commitment and enthusiasm for the network. Our center, comprised of physician investigators at The Ohio State University Wexner Medical Center (OSUWMC) and Nationwide Children's Hospital (NCH), has contributed substantially to the success of NeuroNEXT and is one of the few centers selected to enroll in all eight funded studies. Membership in NeuroNEXT has had a meaningful impact for Ohio State Neurology by providing our patients with important new opportunities for research participation and contributing to a programmatic cultural shift towards more investigator-initiated NIH- funded clinical studies. Ohio State Neurology was a leader in multiple important performance metrics, including the number of randomized or confirmed subjects (top site), efficiency in starting new trails (third fastest) and data accuracy (fourth). We build upon our success to maintain and optimize our NeuroNEXT infrastructure. The leadership administration will be simplified to consist of four key personnel. Collaboration within the our NeuroNEXT Center will be coordinated between site leadership and a large pool of experienced, reliable and motivated potential co-investigators that span all areas of clinical neuroscience. We will build upon the innovative, multifaceted approach to recruitment and outreach that has made us the most successful recruiting site in NeuroNEXT. We will extend our emphasis on research coordinator advocacy with the creation of a Research Coordinator Recognition Program. We will increase the oversight between the NeuroNEXT leadership and each active study team during the course of each study. We energetically support the emphasis on career development in the next cycle of NeuroNEXT. We will implement the NeuroNEXT Clinical Trial Fellowship to expand the pool of experienced clinical investigators and research staff who will be leaders of multicenter clinical research trials. The NeuroNEXT Fellow at OSU will be required to submit a clinical study proposal to the NeuroNEXT Network by the end of the two-year Fellowship period. Clear expectations and milestone requirements will be made and formalized in an Individual Development Plan (IDP) detailing curriculum and training timelines. A mandatory mentorship committee will be formed consisting of NeuroNEXT leadership, a primary mentor and a biostatistician provided by the OSU Neurological Research Institute to help support the development of Fellow projects. The IDP will be updated and reviewed quarterly by a mentorship committee and curriculum will link to existing training infrastructure at OSUWMC and NINDS. In the second year, a “Five Year Plan” for the next phase of protected training time will be formalized that is integrated with existing pre-K and K award opportunities. Thus, NeuroNEXT Fellows will have a high likelihood to sustain their momentum and successfully transition to an independent, funded and productive clinical trialist.

俄亥俄州立大学神经科学临床试验中心卓越网络是最初的 NeuroNEXT 中心之一，我们的中心由俄亥俄州立大学韦克斯纳医学中心 (OSUWMC) 的医师研究人员组成。和全国儿童医院 (NCH) 为 NeuroNEXT 的成功做出了重大贡献，并且是少数被选中参加所有八项资助研究的中心之一，NeuroNEXT 的会员资格为我们的患者提供了有意义的影响。俄亥俄州立大学神经病学在多项重要绩效指标方面处于领先地位，包括随机或确认受试者的数量（顶部网站）、效率。在启动新试验（第三快）和数据准确性（第四）方面，我们将在维护和优化 NeuroNEXT 基础设施方面取得成功。我们的 NeuroNEXT 中心内的协作将得到简化，由四名关键人员组成。现场领导和大型企业之间我们将建立在临床神经科学各个领域的经验丰富、可靠且积极主动的潜在共同研究者的基础上，这使我们成为 NeuroNEXT 中最成功的招募网站。研究协调员倡导，创建研究协调员认可计划。我们将在每项研究过程中加强 NeuroNEXT 领导层和每个活跃研究团队之间的监督。我们大力支持 NeuroNEXT 下一个周期对职业发展的重视。将实施NeuroNEXT 临床试验奖学金旨在扩大经验丰富的临床研究人员和研究人员的队伍，他们将成为多中心临床研究试验的领导者，俄勒冈州立大学的 NeuroNEXT 研究员将需要在两年结束前向 NeuroNEXT 网络提交临床研究提案。将在个人发展计划 (IDP) 中制定明确的期望和里程碑要求，详细说明课程和培训时间表，并由 NeuroNEXT 领导层、主要导师和生物统计学家组成。 OSU 神经学研究所帮助支持研究员项目的开发，指导委员会将每季度更新和审查一次，课程将与 OSUWMC 和 NINDS 的现有培训基础设施相联系。第二年，将制定“五年计划”。下一阶段的受保护培训时间将与现有的 pre-K 和 K 奖励机会相结合，因此，NeuroNEXT 研究员将很有可能保持其势头并成功过渡为独立、有资金和富有成效的临床试验人员。